Most of the plastic products we use are made through injection molding, a process in which molten plastic is injected into a ...

French AI startup Mistral launched its new Mistral 3 family of open-weight models on Tuesday, a launch that aims to prove it can lead in making AI publicly available and serve business clients better ...

Sometimes we assume the people and things around us are neutral or hostile to our existence. What if the opposite could be true? By Melissa Kirsch Normally I pass my morning commute absorbed in a book ...

Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. The novel therapy ...

ZURICH, Sept 11 (Reuters) - Swiss lawmakers are seeking to water down government proposals to help prevent financial crime, saying the country needs to stay competitive in global cross-border wealth ...

Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...

In forecasting economic time series, statistical models often need to be complemented with a process to impose various constraints in a smooth manner. Systematically imposing constraints and retaining ...

AMSTERDAM, Aug 25 (Reuters) - Dutch online bank Bunq has received a 2.6 million euro ($3.04 million) fine for failures in its money laundering controls, Dutch central bank DNB said on Monday. Bunq ...

When you buy through links on our articles, Future and its syndication partners may earn a commission. Credit: Robert Knight Archive/Redferns Open tunings are very popular with slide players as they ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The deal will allow AML ...

Adding magrolimab to venetoclax and azacitidine did not improve overall survival or complete remission rates in patients with previously untreated acute myeloid leukemia (AML) who were ineligible for ...

Ivosidenib combined with azacitidine extended median overall survival to 29.3 months compared with 7.9 months for placebo plus azacitidine in newly diagnosed isocitrate dehydrogenase 1 (IDH1)-mutated ...